NextCure Inc reports results for the quarter ended in September - Earnings Summary

NextCure

02/11/2023 21:57

* NextCure Inc  NXTC.OQ  reported a quarterly adjusted loss
of 51
cents​​ per share for the quarter ended in September, higher
than the same quarter last year, when the company reported EPS
of -68 cents.  The mean expectation of four analysts for the
quarter was for a loss of 66 cents per share. Wall Street
expected results to range from -68 cents to -63 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NextCure Inc's reported EPS for the quarter was a loss
of 51
cents​.
    * The company reported a quarterly loss of $14.3 million.
    * NextCure Inc shares had fallen by 17.1% this quarter and
lost 24.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for NextCure Inc is
$6.00 
This summary was machine generated from LSEG data November 2 at
09:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.66          -0.51          Beat
 Jun. 30 2023      -0.59          -0.64          Missed
 Mar. 31 2023      -0.62          -0.58          Beat
 Dec. 31 2022      -0.66          -0.62          Beat